- Home
- LNT vs GMAB Comparison
LNT vs GMAB Comparison
Compare LNT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNT | GMAB |
|---|---|---|
| Founded | 1917 | 1999 |
| Country | United States | Denmark |
| Employees | 2998 | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 17.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LNT | GMAB |
|---|---|---|
| Price | $65.81 | $31.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $69.38 | $40.40 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 23.58 | ★ 132.41 |
| EPS | 3.18 | ★ 25.10 |
| Revenue | ★ $4,274,000,000.00 | $3,845,670,022.00 |
| Revenue This Year | $7.01 | $24.85 |
| Revenue Next Year | $4.72 | $16.67 |
| P/E Ratio | $20.59 | ★ $12.31 |
| Revenue Growth | 7.77 | ★ 29.57 |
| 52 Week Low | $56.30 | $17.24 |
| 52 Week High | $69.75 | $33.65 |
Technical Indicators
Market Signals| Indicator | LNT | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 59.84 |
| Support Level | $67.10 | $31.32 |
| Resistance Level | $69.50 | $32.41 |
| Average True Range (ATR) | 0.95 | 0.64 |
| MACD | -0.32 | 0.11 |
| Stochastic Oscillator | 6.35 | 73.67 |
Price Performance
Historical ComparisonAbout LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.